Cycloxan 500 (Cyclophosphamide) Injection IP
Cycloxan 500 mg Injection is an anti-cancer medication. It is an alkylating agent which works by damaging the genetic material (DNA and RNA) of the cancer cells, thereby stopping their growth and multiplication. It is also used to treat kidney disease known as nephrotic syndrome in children after other treatments have not worked.
| Brand Name | Cycloxan |
| Generic Name | Cyclophosphamide |
| Strength | 500 mg |
| Manufacturer | Zydus Lifescience Ltd |
Product Overview
Cycloxan 500mg Injection is used in the treatment of various cancers to help shrink tumors, slow disease progression, and improve the effectiveness of other treatments. It can support better outcomes and quality of life during cancer therapy.
Answers to What Matters
Strengthening healthcare delivery through long-standing collaborations built on quality, reliability, and shared purpose.
We supply a comprehensive range of essential, specialty, super specialty, and critical care pharmaceutical products across multiple therapeutic segments.
Yes, we cater to all pin codes in India and ensure delivery through reliable courier services.
We work with hospitals, pharmacies, clinics, healthcare institutions, distributors, and patients through approved supply channels.
Yes. We provide prompt support for urgent and critical medicine needs, subject to availability and compliance requirements.
All products are sourced from authorised manufacturers and handled under strict GDP-compliant storage, documentation, and distribution protocols.
We accept multiple payment modes, including bank transfer, UPI, and other approved digital payment options, as per applicable terms.
Our team typically responds within one business working day.
Yes. Home delivery is available where permitted, ensuring safe and compliant last-stage delivery of medicines.
You can reach us through the enquiry form on our website or contact our team directly for assistance.
Let’s Build a Reliable Pharma Partnership
Reach out to explore how we can support your pharma requirements.
